Source: PR Newswire

Press Release: Heron : Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI, SUSTOL, and APONVIE as Alternatives During the Potential Shortage of Intravenous Fluids

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today reaffirmed the Company's...

Read full article »
Annual Revenue
$100-500M
Employees
100-250
Craig Collard's photo - CEO of Heron

CEO

Craig Collard

CEO Approval Rating

82/100

Read more